Reducing Lipase Activity in Recombinant Protein Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biopharmaceutical manufacturing faces challenges in stabilizing recombinant proteins due to polysorbate degradation, primarily caused by endogenous lipoprotein lipase (LPL) from CHO host cells, which co-purifies with therapeutic proteins and degrades polysorbates, affecting product stability and shelf-life.
Innovation Solution
The development of non-naturally occurring host cells with reduced LPL production, achieved through methods like expressing interfering RNAs (siRNAs, shRNAs) or knocking out LPL genes, to minimize LPL presence and activity, thereby stabilizing recombinant proteins and polysorbates in formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polysorbate is added to improve therapeutic protein stability, then protein stability is improved, but polysorbate degradation occurs over time due to endogenous lipase activity
Solution Approach 1:
The patent removes the harmful endogenous lipase (LPL) from the host cell through gene knockout or RNA interference, thereby eliminating the source of polysorbate degradation while preserving the beneficial polysorbate-stabilized protein formulation
Solution Approach 2:
The patent introduces an inhibitor molecule that mediates between the endogenous lipase and polysorbate, blocking the enzymatic degradation pathway and allowing polysorbate to maintain its stabilizing function without being degraded
2Reliability
If endogenous lipase production is reduced in host cells, then polysorbate stability is improved, but host cell engineering complexity increases
Solution Approach 1:
The patent replaces complex mechanical purification processes with biological control mechanisms (gene knockout or RNAi) that inherently prevent lipase production at the source, simplifying the overall manufacturing process despite the genetic engineering step
Solution Approach 2:
The patent fundamentally changes the biological parameter of lipase production capacity in the host cell through genetic modification, transforming the cell from a lipase-producing system to a lipase-free system for stable polysorbate formulations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces LPL-mediated polysorbate degradation, ensuring that at least 90% of recombinant proteins remain stable over extended periods, maintaining biological activity and product quality.
Implementation Method 1
The host cell may express an interfering RNA specific for the endogenous lipase (e.g., LPL). The interfering RNA may be selected from the group consisting of small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), and bifunctional RNAs.
Implementation Method 2
The endogenous lipase (e.g., LPL) is present in the composition in a small amount (e.g., less than about 10%, 5%, 1%, 0.1%, 0.01%, 0.001% or 0.0001% by weight), and is capable of degrading the polysorbate.
Implementation Method 3
At least one copy of an endogenous gene encoding the endogenous lipase (e.g., LPL) may be knocked out from the genome of the host cell. Preferably, all copies of the endogenous gene are knocked out.
Data Source
AI summary
The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.